Skip NavigationSkip to Content

Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health

  1. Author:
    Cheng, Feixiong
    Liang, Han
    Butte, Atul J.
    Eng, Charis
    Nussinov, Ruth
  2. Author Address

    Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA.Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA.Case Western Reserve Univ, Sch Med, CASE Comprehens Canc Ctr, Cleveland, OH USA.Case Western Reserve Univ, Sch Med, Dept Genet & Genome Sci, Cleveland, OH USA.Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.Univ Calif San Francisco, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA.Univ Calif Hlth, Ctr Data Driven Insights & Innovat, Oakland, CA USA.Leidos Biomed Res Inc, Canc & Inflammat Program, Frederick Natl Lab Canc Res, Natl Canc Inst Frederick, Frederick, MD USA.Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Sch Med, Tel Aviv, Israel.
    1. Year: 2019
    2. Date: Jan
    3. Epub Date: 2018 12 13
  1. Journal: Pharmacological reviews
  2. AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS,
    1. 71
    2. 1
    3. Pages: 1-19
  3. Type of Article: Review
  4. ISSN: 0031-6997
  1. Abstract:

    Recent remarkable advances in genome sequencing have enabled detailed maps of identified and interpreted genomic variation, dubbed "mutanomes." The availability of thousands of exome/genome sequencing data has prompted the emergence of new challenges in the identification of novel druggable targets and therapeutic strategies. Typically, mutanomes are viewed as one- or two-dimensional. The three-dimensional protein structural view of personal mutanomes sheds light on the functional consequences of clinically actionable mutations revealed in tumor diagnosis and followed up in personalized treatments, in a mutanome-informed manner. In this review, we describe the protein structural landscape of personal mutanomes and provide expert opinions on rational strategies for more streamlined oncological drug discovery and molecularly targeted therapies for each individual and each tumor. We provide the structural mechanism of orthosteric versus allosteric drugs at the atom-level via targeting specific somatic alterations for combating drug resistance and the "undruggable" challenges in solid and hematologic neoplasias. We discuss computational biophysics strategies for innovative mutanome-informed cancer immunotherapies and combination immunotherapies. Finally, we highlight a personalmutanome infrastructure for the emerging development of personalized cancer medicine using a breast cancer case study.

    See More

External Sources

  1. DOI: 10.1124/pr.118.016253
  2. PMID: 30545954
  3. PMCID: PMC6294046
  4. WOS: 000460336600001

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel